CHMP adopted a request for supplementary information with a specific timetable regarding the proposed extension of indication for Cosentyx to treat adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa who have an inadequate response to conventional systemic HS therapy, based on modelling and extrapolation of existing data. (European Medicines Agency) - Oct 17, 2026 - CHMP Final Minutes of the
meeting on 20 - 23 Jul 2026: The Committee discussed clinical, product
information, and risk management plan aspects. The proposed variation includes
updates to sections 4.1, 4.2, 5.1, and 5.2 of the SmPC, along with
corresponding revisions to the Package Leaflet.
CHMP • Hidradenitis Suppurativa • Immunology
|